Pulmonx reports positive CONVERT trial results for AeriSeal emphysema system
+1 new source since this summary was written
Pulmonx announced publication of CONVERT Trial results for its AeriSeal System in severe emphysema patients. AeriSeal converted collateral ventilation status in 75.8% of evaluable patients, after which 88.9% achieved target-lobe volume reduction with Zephyr Valves at 45 days; the reduction continued through 12 months. Pulmonx is enrolling the CONVERT II Pivotal Trial to support a U.S. Premarket Approval application for AeriSeal.
Why it matters
AeriSeal remains under clinical evaluation, so U.S. commercialization depends on the ongoing CONVERT II study and its intended six-month results. The reported outcomes expand the potential group of emphysema patients who could qualify for subsequent Zephyr Valve treatment, while the company continues pursuing FDA approval.
Key facts
- 1The CONVERT Trial enrolled 101 patients across 14 sites in Europe and Australia. investing.com
- 2AeriSeal converted collateral ventilation positive lobes to collateral ventilation negative status in 75.8% of evaluable patients. investing.com
- 3At 45 days after Zephyr Valve placement, 88.9% of evaluable patients achieved target-lobe volume reduction, which persisted through 12 months. investing.com
- 4CONVERT II is designed to enroll approximately 200 patients internationally and in the United States under an Investigational Device Exemption. investing.com
- 5Six-month CONVERT II results are intended to support Pulmonx’s U.S. Premarket Approval application for AeriSeal. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.